公开(公告)号：US20230219993A1

公开(公告)日：2023-07-13

申请号：US17996430

申请日：2021-04-16

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

发明人： Yuanchao XIE ,  Gengfu XIAO ,  Yang HE ,  Leike ZHANG ,  Heji Akber AISA ,  Hualiang JIANG ,  Jingshan SHEN

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US20230312584A1

公开(公告)日：2023-10-05

申请号：US18033673

申请日：2021-10-21

申请人： VIGONVITA LIFE SCIENCES CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

发明人： Jingshan SHEN ,  Yuanchao XIE ,  Leike ZHANG ,  Gengfu XIAO ,  Zhen WANG ,  Hualiang JIANG ,  Huaqiang XU ,  Tianwen HU ,  Guanghui TIAN

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  C07B2200/13

摘要： A salt of nucleoside analog, and crystal form, pharmaceutical composition and use thereof. The salt of nucleoside analog has a structure shown in formula I, wherein X is hydrogen or deuterium; Y is an acid, n is 0.5 to 2, or n is 1. When X is hydrogen or deuterium, Y is hydrogen bromide, and n is 1, the salt of the nucleoside analog exists in the form of a crystal with crystal form I or crystal form A or exists in an amorphous form.

公开(公告)号：US20240140975A1

公开(公告)日：2024-05-02

申请号：US18519408

申请日：2023-11-27

申请人： Shanghai Institute of Materia Medica, Chinese Academyof Sciences ,  Wuhan Institute ofVirology, Chinese Academy of Science ,  Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science ,  Vigonvita Life Sciences Co., Ltd.

发明人： Yuanchao XIE ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.